Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Chronic Hepatitis B

In brief

The primary objective of this study is to evaluate the antiviral efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) versus placebo in pediatric population (aged 2 to \< 12 years at the time of enrollment) with chronic hepatitis B (CHB) infection.

Key facts

Study ID
NCT01651403
Run by
Gilead Sciences
People needed
90
Starts
2012-12-06
Expected to finish
2027-07-01
Last updated by the study team
2026-01-30

Who can join

Age: 2 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.